Vermillion (VRML) Shares on the Move as Co. Gets Patent for Platelet Biomarkers for Cancer
Tweet
Share
E-mailGet Alerts VRML Hot Sheet
Join SI Premium – FREE
Shares of Vermillion (Nasdaq: VRML) have just surged in mid-day trade Tuesday as Bloomberg is reporting the company has received a patent for its platelet biomarkers for cancer.
The stock last traded at $2.10, up more than 12 percent for the session.
The stock last traded at $2.10, up more than 12 percent for the session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Nuvectis Pharma (NVCT) files $200M mixed shelf
- BIGG Digital Assets to rename as Surge Digital, consolidate shares
Create E-mail Alert Related Categories
Corporate News, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
